Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| AcroQoL: Acromegaly Quality of Life Questionnaire× | ThyPRO: Kiwango cha Matokeo Yanayoripotiwa na Mgonjwa Kuhusu Tezi Dume× | |
|---|---|---|
| Nyanja | Endokrinolojia | Endokrinolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2006 | 2009 |
| Mwanzilishi≠ | Markus Buchfelder, Dieter Weigel, Monica Droste, et al. | Torquil Watt, Jens Bjørner, Marianne Groenvold |
| Aina | Patient self-report questionnaire | Patient self-report questionnaire |
| Chanzo asilia≠ | Buchfelder, M., Weigel, D., Droste, M., et al. (2006). The quality of life of acromegaly patients is markedly impaired: Data from the German Acromegaly Registry. Eur J Endocrinol, 150(4), 541-549. link ↗ | Watt, T., Bjorner, J. B., Groenvold, M., et al. (2009). Establishing construct validity for the thyroid-related patient reported outcomes (ThyPRO): An initial examination. J Clin Endocrinol Metab, 94(9), 3572-3580. link ↗ |
| Majina mbadala | Acromegaly QoL, Acro-QoL | ThyPRO-85, ThyPRO-39 |
| Zinazohusiana | 3 | 3 |
| Muhtasari≠ | AcroQoL is a disease-specific 22-item quality of life questionnaire developed to assess the multidimensional burden of acromegaly, a chronic growth hormone-secreting pituitary tumor disorder. Developed by Buchfelder and colleagues in 2006, it captures physical complications (joint/bone pain, carpal tunnel syndrome, metabolic disease), appearance-related concerns (facial changes, hand/foot enlargement), and psychological/social impacts (mood, social limitation, body image). It is the primary outcome measure for assessing quality of life in acromegaly treatment trials and clinical practice. | ThyPRO is a comprehensive patient-reported outcome measure assessing the quality of life impact of thyroid disease and its treatment across 13 dimensions. Developed by Watt and colleagues in 2009, it is the most extensively validated thyroid-specific instrument, covering both physical and psychological domains relevant to patients with hyperthyroidism, hypothyroidism, and thyroid cancer. |
| ScholarGateSeti ya data ↗ |
|
|